Celgene, the company that manufactures Revlimid, seems to be about to be taken over by a bigger company. Does anyone know anything about this, and what the implications are for those of us who take Revlimid?
There was an article in the Times newspaper on 4 January this year about the possibility of Celgene being taken over by Bristol Meyers Squibb. They mentioned Revlimid and said that the likely expiry date of the patent was 2022. I think the staff in Myeloma UK keep in touch with these developments and are probably best placed to know if there are going to be any implications which affect us patients.
davidainsdale 5 years, 8 months ago.
